Macintyre Lynsey, Zhang Tong, Viegelmann Christina, Martinez Ignacio Juarez, Cheng Cheng, Dowdells Catherine, Abdelmohsen Usama Ramadam, Gernert Christine, Hentschel Ute, Edrada-Ebel RuAngelie
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK.
Department of Botany II, Julius-von-Sachs Institute for Biological Sciences, University of Würzburg, Julius-von-Sachs-Platz 3, D-97082 Würzburg, Germany.
Mar Drugs. 2014 Jun 5;12(6):3416-48. doi: 10.3390/md12063416.
Marine invertebrate-associated symbiotic bacteria produce a plethora of novel secondary metabolites which may be structurally unique with interesting pharmacological properties. Selection of strains usually relies on literature searching, genetic screening and bioactivity results, often without considering the chemical novelty and abundance of secondary metabolites being produced by the microorganism until the time-consuming bioassay-guided isolation stages. To fast track the selection process, metabolomic tools were used to aid strain selection by investigating differences in the chemical profiles of 77 bacterial extracts isolated from cold water marine invertebrates from Orkney, Scotland using liquid chromatography-high resolution mass spectrometry (LC-HRMS) and nuclear magnetic resonance (NMR) spectroscopy. Following mass spectrometric analysis and dereplication using an Excel macro developed in-house, principal component analysis (PCA) was employed to differentiate the bacterial strains based on their chemical profiles. NMR 1H and correlation spectroscopy (COSY) were also employed to obtain a chemical fingerprint of each bacterial strain and to confirm the presence of functional groups and spin systems. These results were then combined with taxonomic identification and bioassay screening data to identify three bacterial strains, namely Bacillus sp. 4117, Rhodococcus sp. ZS402 and Vibrio splendidus strain LGP32, to prioritize for scale-up based on their chemically interesting secondary metabolomes, established through dereplication and interesting bioactivities, determined from bioassay screening.
与海洋无脊椎动物相关的共生细菌会产生大量新型次生代谢产物,这些产物在结构上可能具有独特性,并具有有趣的药理特性。菌株的选择通常依赖于文献检索、基因筛选和生物活性结果,在耗时的生物测定导向分离阶段之前,往往不考虑微生物产生的次生代谢产物的化学新颖性和丰度。为了快速推进选择过程,利用代谢组学工具,通过液相色谱-高分辨率质谱(LC-HRMS)和核磁共振(NMR)光谱研究从苏格兰奥克尼群岛冷水海洋无脊椎动物中分离出的77种细菌提取物的化学图谱差异,以辅助菌株选择。在进行质谱分析并使用内部开发的Excel宏进行去重复后,采用主成分分析(PCA)根据细菌菌株的化学图谱对其进行区分。还采用了核磁共振1H和相关光谱(COSY)来获取每个细菌菌株的化学指纹,并确认官能团和自旋系统的存在。然后将这些结果与分类鉴定和生物测定筛选数据相结合,以鉴定出三种细菌菌株,即芽孢杆菌属4117、红球菌属ZS402和灿烂弧菌菌株LGP32,根据通过去重复确定的具有化学意义的次生代谢组和生物测定筛选确定的有趣生物活性,对它们进行优先扩大培养。